Optimizing R&D Resource Allocation for Enterprise Innovation Team's in Ethiopia
International Journal of Finance and Investment · 2025
DOI: 10.54097/2b11cs32 ↗At a glance
Journal article in International Journal of Finance and Investment, 2025. Written by Ashenafi Hailemichael Mesfin. 15 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
This paper examines the optimal strategies for distributing limited R&D resources, considering the impact of governmental incentives and intra-enterprise competition teams in Ethiopia. We investigate that Success probabilities are increasing likelihood of innovation success with enhanced resource and effort inputs, but with diminishing returns. Equilibrium analysis and optimization problems, solved via MATLAB simulations, illustrate how resource allocation can significantly enhance innovation efficiency. We find while focusing resources on a single team may maximize outputs under specific conditions, distributing resources across multiple teams can promote beneficial competition and exploit diverse capabilities, thus optimizing the overall innovation within enterprises. This paper contributes valuable insights to strategic management in Ethiopia by outlining mathematical methods through which Ethiopian enterprises can maximize their innovation potential in the midst of resource constraints and competitive dynamics.
Cite
APA
Mesfin, A. H. (2025). Optimizing R&D Resource Allocation for Enterprise Innovation Team's in Ethiopia. International Journal of Finance and Investment. https://doi.org/10.54097/2b11cs32
Vancouver
Mesfin AH. Optimizing R&D Resource Allocation for Enterprise Innovation Team's in Ethiopia. International Journal of Finance and Investment. 2025. doi:10.54097/2b11cs32
BibTeX
@article{Mesfin2025,
author = {Mesfin, Ashenafi Hailemichael},
title = {Optimizing R&D Resource Allocation for Enterprise Innovation Team's in Ethiopia},
journal = {International Journal of Finance and Investment},
year = {2025},
doi = {10.54097/2b11cs32}
}
EUVIMED